What is the role of alternative biomarkers for coronary heart disease?

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Predictive models for future risk of coronary heart disease (CHD) based on traditional risk factors, such as age, male gender, LDL cholesterol, HDL cholesterol, diabetes mellitus, hypertension, smoking and family history of premature CHD, are quite robust but leave room for further improvement. Thus, efforts are being made to assess additional biomarkers for CHD, such as, lipoprotein (a), C-reactive protein, fibrinogen, lipoprotein-associated phospholipase A2, homocysteine and others. However, none of the novel biomarkers has demonstrated improved prediction beyond traditional risk factor models in a consistent fashion across multiple cohorts. Many criteria have to be fulfilled before a biomarker can be considered clinically relevant. Another way is to develop new models predicting long-term or life-time risk of CHD. Further research using novel biomarkers and long-term predictive models has the potential to improve CHD risk prediction.

Original languageEnglish (US)
Pages (from-to)289-293
Number of pages5
JournalClinical Endocrinology
Volume75
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Coronary Disease
Biomarkers
1-Alkyl-2-acetylglycerophosphocholine Esterase
Lipoprotein(a)
Homocysteine
C-Reactive Protein
LDL Cholesterol
Fibrinogen
HDL Cholesterol
Diabetes Mellitus
Smoking
Hypertension
Research

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

What is the role of alternative biomarkers for coronary heart disease? / Garg, Abhimanyu.

In: Clinical Endocrinology, Vol. 75, No. 3, 09.2011, p. 289-293.

Research output: Contribution to journalArticle

@article{6d7a81731eba4d39a8afe68395799bd7,
title = "What is the role of alternative biomarkers for coronary heart disease?",
abstract = "Predictive models for future risk of coronary heart disease (CHD) based on traditional risk factors, such as age, male gender, LDL cholesterol, HDL cholesterol, diabetes mellitus, hypertension, smoking and family history of premature CHD, are quite robust but leave room for further improvement. Thus, efforts are being made to assess additional biomarkers for CHD, such as, lipoprotein (a), C-reactive protein, fibrinogen, lipoprotein-associated phospholipase A2, homocysteine and others. However, none of the novel biomarkers has demonstrated improved prediction beyond traditional risk factor models in a consistent fashion across multiple cohorts. Many criteria have to be fulfilled before a biomarker can be considered clinically relevant. Another way is to develop new models predicting long-term or life-time risk of CHD. Further research using novel biomarkers and long-term predictive models has the potential to improve CHD risk prediction.",
author = "Abhimanyu Garg",
year = "2011",
month = "9",
doi = "10.1111/j.1365-2265.2011.04045.x",
language = "English (US)",
volume = "75",
pages = "289--293",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - What is the role of alternative biomarkers for coronary heart disease?

AU - Garg, Abhimanyu

PY - 2011/9

Y1 - 2011/9

N2 - Predictive models for future risk of coronary heart disease (CHD) based on traditional risk factors, such as age, male gender, LDL cholesterol, HDL cholesterol, diabetes mellitus, hypertension, smoking and family history of premature CHD, are quite robust but leave room for further improvement. Thus, efforts are being made to assess additional biomarkers for CHD, such as, lipoprotein (a), C-reactive protein, fibrinogen, lipoprotein-associated phospholipase A2, homocysteine and others. However, none of the novel biomarkers has demonstrated improved prediction beyond traditional risk factor models in a consistent fashion across multiple cohorts. Many criteria have to be fulfilled before a biomarker can be considered clinically relevant. Another way is to develop new models predicting long-term or life-time risk of CHD. Further research using novel biomarkers and long-term predictive models has the potential to improve CHD risk prediction.

AB - Predictive models for future risk of coronary heart disease (CHD) based on traditional risk factors, such as age, male gender, LDL cholesterol, HDL cholesterol, diabetes mellitus, hypertension, smoking and family history of premature CHD, are quite robust but leave room for further improvement. Thus, efforts are being made to assess additional biomarkers for CHD, such as, lipoprotein (a), C-reactive protein, fibrinogen, lipoprotein-associated phospholipase A2, homocysteine and others. However, none of the novel biomarkers has demonstrated improved prediction beyond traditional risk factor models in a consistent fashion across multiple cohorts. Many criteria have to be fulfilled before a biomarker can be considered clinically relevant. Another way is to develop new models predicting long-term or life-time risk of CHD. Further research using novel biomarkers and long-term predictive models has the potential to improve CHD risk prediction.

UR - http://www.scopus.com/inward/record.url?scp=79961238924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961238924&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2011.04045.x

DO - 10.1111/j.1365-2265.2011.04045.x

M3 - Article

C2 - 21521314

AN - SCOPUS:79961238924

VL - 75

SP - 289

EP - 293

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -